⌕
UroGen Pharma · URGN · Nasdaq
Tenet 44 · Weak
Compare
$29.87+6.30%At closeTenet 44 · Weak
$29.87+1.77 (+6.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

UroGen Pharma (URGN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is URGN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 9, 2026 · 08:35 ET
UroGen: Opportunity Builds As Rough Patch Gets Brutal

UroGen Pharma is rated a 'Buy' at a depressed ~$1.21B market cap, with potential for ~65% upside in 2027. Management has established a promising setup, featuring two approved products—Jelmyto and Zusdori—leveraging the p…

URGN +6.3% todayRead at source ↗
● MarketBeatNov 4, 2026 · 17:15 ET
Urogen Pharma Q3 Earnings Call Highlights

Urogen Pharma NASDAQ: URGN reported third-quarter revenue of $89 million, more than triple the $27.5 million recorded a year earlier, as sales of bladder cancer treatment ZUSDURI continued to grow. The company said it ex…

URGN +6.3% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 15:54 ET
UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript

UroGen Pharma Ltd. ( URGN ) Q3 2026 Earnings Call November 4, 2026 10:00 AM EST Company Participants Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO & Director Mark Schoenberg -…

URGN +6.3% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 11:06 ET
Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue Estimates

Urogen Pharma (URGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $0.69 per share a year ago.…

URGN +6.3% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

ZUSDURI ® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen's NDA for UGN-103 (next-generation novel mitomycin-based formulation) for re…

URGN +6.3% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 08:00 ETCOMPANY'S OWN WORDS
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.…

URGN +6.3% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

Phase 1 clinical trial to evaluate local intravesical administration of UGN-501 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumo…

URGN +6.3% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 08:00 ET
UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer

Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTO Results demonstrate sustained disease control through extended follow-up among pat…

URGN +6.3% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 18:00 ETCOMPANY'S OWN WORDS
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026

Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET…

URGN +6.3% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 08:00 ETCOMPANY'S OWN WORDS
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today …

URGN +6.3% todayRead at source ↗
● Seeking AlphaOct 13, 2026 · 07:09 ET
UroGen Pharma: An Emerging GARP Stock

UroGen Pharma has pulled back 30% after a 208% rally, driven by Zusduri's strong launch as the only approved non-surgical LG-IR-NMIBC therapy. Zusduri's rapid uptake, favorable patient preference, and robust clinical dat…

URGN +6.3% todayRead at source ↗
● Defense WorldOct 12, 2026 · 02:15 ET
Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Price Target of $52.38 According to Analysts

Shares of Urogen Pharma (NASDAQ: URGN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten brokerages that are presently covering the stock, Marketbeat reports. One research analyst h…

URGN +6.3% todayRead at source ↗
● Zacks Investment ResearchSep 30, 2026 · 11:16 ET
Here's Why You Should Add URGN Stock to Your Portfolio Now

UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.…

URGN +6.3% todayRead at source ↗
● Defense WorldSep 10, 2026 · 03:45 ET
Critical Analysis: Zoetis (NYSE:ZTS) and Urogen Pharma (NASDAQ:URGN)

Zoetis (NYSE: ZTS - Get Free Report) and Urogen Pharma (NASDAQ: URGN - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their an…

URGN +6.3% todayRead at source ↗
● Seeking AlphaSep 9, 2026 · 09:54 ET
Urogen Pharma: Upside After Bladder Cancer Launch

UroGen Pharma Ltd. has transitioned into a commercial-stage biopharma, driven by strong adoption of Zusduri for recurrent non-muscle invasive bladder cancer. Zusduri achieved an 80% complete response rate in the ENVISION…

URGN +6.3% todayRead at source ↗
● GlobeNewsWireSep 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today…

URGN +6.3% todayRead at source ↗
● GlobeNewsWireSep 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.…

URGN +6.3% todayRead at source ↗
● Defense WorldAug 30, 2026 · 04:30 ET
BlackRock Inc. Purchases Shares of 3,201,461 Urogen Pharma $URGN

BlackRock Inc. purchased a new position in Urogen Pharma (NASDAQ: URGN) in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,201…

URGN +6.3% todayRead at source ↗
● Zacks Investment ResearchAug 21, 2026 · 10:56 ET
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet

The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions coul…

URGN +6.3% todayRead at source ↗
● PRNewsWireAug 20, 2026 · 07:05 ET
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable susta…

URGN +6.3% todayRead at source ↗
● GlobeNewsWireAug 20, 2026 · 07:00 ETCOMPANY'S OWN WORDS
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acq…

URGN +6.3% todayRead at source ↗

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just URGN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.